Funxional Therapeutics completes Phase I study of FX125L

Jan 8 2010

Funxional Therapeutics Ltd (Funxional) has announced today the successful completion of the Phase I programme of its novel anti-inflammatory, FX125L, an orally available small molecule that belongs to a new therapeutic class named Broad Spectrum Chemokine Inhibitors (BSCIs).

“The results of the multiple dose study were entirely consistent with those of the single dose study and confirmed the excellent drug-like profile of FX125L”

Following the successful completion of the single ascending dose study in July 2009, a multiple ascending dose study, in which FX125L was administered orally once-daily in healthy subjects, was conducted also in the United States. This second Phase I study confirmed the excellent safety, tolerability and PK profile of FX125L and provided data consistent with an interaction of FX125L with its target receptor. Complete results of the study will be presented in a future scientific meeting.

“The results of the multiple dose study were entirely consistent with those of the single dose study and confirmed the excellent drug-like profile of FX125L” said Konstantinos Efthymiopoulos, CEO of Funxional Therapeutics. “We are now starting the preparation of the Phase II studies with FX125L in different inflammatory conditions and anticipate the initiation of these studies in the US and Europe in the second quarter of 2010”.